Access Restriction

Source CiteSeerX
Content type Text
File Format PDF
Subject Domain (in DDC) Computer science, information & general works ♦ Data processing & computer science
Subject Keyword Mild Cognitive Impairment ♦ Cerebrospinal Fluid ♦ Amino-truncated Amyloid42 Peptide ♦ Amino Terminus ♦ Alzheimer Disease ♦ Clinical Diagnosis ♦ Drug Development ♦ A42 Peptide Concentration ♦ Monoclo-nal Antibody ♦ Essential Step ♦ Discriminant Ability ♦ Different A42 Peptide ♦ Different Amyloid42 ♦ Early Identification ♦ Xmap Technology ♦ Cerebrospi-nal Fluid
Abstract Background: Early identification of patients with mild cognitive impairment (MCI) progressing to Alzheimer disease (MCI-AD) by use of biomarkers in cerebrospi-nal fluid (CSF) is an essential step toward improving clinical diagnosis and drug development. We evaluated whether different -amyloid42 (A42) peptides can add further information to the combined use of tau and A1–42 for predicting risk of progression of MCI to AD. Methods: We used xMAP ® technology to simulta-neously quantify different A42 peptides modified at the amino terminus, tau, and phosphorylated tau (P-tau181P) in CSF. A42 peptide concentrations were mea-sured by use of immunoreactivity toward A monoclo-nal antibodies [3D6 (A42-3D6), WO2 (A42-WO2), 6E10 (A42-6E10), and 4G8 (A42-4G8)]. The discriminant ability
Educational Role Student ♦ Teacher
Age Range above 22 year
Educational Use Research
Education Level UG and PG ♦ Career/Technical Study